Brainstorm Cell Therapeutics Inc.
BCLI
Rank in Stocks
#28470
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Share Price
$0.99
Last synced: 2026-11-11
Market Cap
$10.92M
Change (1 day)
1.76%
Change (1 year)
54.69%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Brainstorm Cell Therapeutics Inc. (BCLI)
Category
Healthcare
P/B ratio for Brainstorm Cell Therapeutics Inc. (BCLI)
P/B ratio as of November 2026 TTM: -0.82
According to Brainstorm Cell Therapeutics Inc.'s latest financial reports and stock price, its current price-to-book ratio (TTM) is -0.82. At the end of 2025 the company had a P/B ratio of -0.50.
P/B ratio history for Brainstorm Cell Therapeutics Inc. from 2002 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | -0.82 | 63.66% |
| 2025 | -0.50 | -68.10% |
| 2024 | -1.55 | -52.08% |
| 2023 | -3.24 | -83.76% |
| 2022 | -19.95 | -365.25% |
| 2021 | 7.52 | 74.06% |
| 2020 | 4.32 | -148.25% |
| 2019 | -8.96 | -160.79% |
| 2018 | 14.73 | 16.52% |
| 2017 | 12.64 | 163.85% |
| 2016 | 4.79 | 27.85% |
| 2015 | 3.75 | -68.52% |
| 2014 | 11.91 | -92.50% |
| 2013 | 158.70 | 137,302.68% |
| 2012 | 0.12 | -99.95% |
| 2011 | 248.09 | -144.87% |
| 2010 | -552.94 | 304.33% |
| 2009 | -136.76 | 543.72% |
| 2008 | -21.24 | -81.78% |
| 2007 | -116.61 | 112.65% |
| 2006 | -54.83 | -104.97% |
| 2005 | 1.10K | -122.53% |
| 2004 | -4.90K | -3,025.18% |
| 2003 | 167.36 | 1,821.76% |
| 2002 | 8.71 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 7.0081 | -956.42% |
US
|
|
| 12.9864 | -1,687.00% |
US
|
|
| 4.5726 | -658.79% |
AU
|
|
| 4.5877 | -660.64% |
BE
|
|
| 6.7286 | -922.27% |
NL
|
Questions about Brainstorm Cell Therapeutics Inc.'s P/B ratio
What is Brainstorm Cell Therapeutics Inc.'s P/B ratio?
Brainstorm Cell Therapeutics Inc.'s P/B ratio is -0.82, as of Nov 2026.
What was Brainstorm Cell Therapeutics Inc.'s P/B ratio in 2025?
In 2025, Brainstorm Cell Therapeutics Inc.'s P/B ratio was -0.50, compared with -1.55 in 2024.
How has Brainstorm Cell Therapeutics Inc.'s P/B ratio changed since 2020?
From 2020 to 2025, Brainstorm Cell Therapeutics Inc.'s P/B ratio was highest in 2021 (7.52) and lowest in 2022 (-19.95).
How does Brainstorm Cell Therapeutics Inc.'s P/B ratio compare with similar companies?
Brainstorm Cell Therapeutics Inc.'s P/B ratio (-0.82) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 12.99.